| MRNA |
Return |
5-day cumulative residual |
+2.0% (FADE) |
Print is a placeholder — thin trough revenue (~$80M) and a wide GAAP loss dominated by the Q3 Arbutus payment. Any day-1 weakness on a soft top-line miss/fragile post-rally positioning is likely to fade because the genuinely binary catalyst — the Aug 5 mRNA-1010 flu PDUFA (well de-risked by the unanimous AdCom vote and positive briefing docs) — falls inside the 5-day window; an approval is a fifth product and sentiment win in a hostile policy backdrop, though heavy prior de-risking caps upside and keeps net drift modest. |
LOW |